# Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma

> **NCT00556205** · PHASE2 · WITHDRAWN · sponsor: **Massachusetts General Hospital**

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Sunitinib
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00556205
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-09
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Toxicity of combination from other trials
- **Last updated:** 2016-03-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00556205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00556205, "Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00556205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*